SHANGHAI, Sept. 12, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a Phase 2 clinical...
GENEVA, Jan. 22, 2025 /PRNewswire/ -- ID Quantique (IDQ), a global leader in Quantum-Safe solutions and Quantum Communications, today announced that its high-performance Clavis XG...